Table 1.
Included studies characteristics.
| Author | Study year | Country | Type of cancer | Number of participants | Intervention | Control | Randomization ratio | Primary or relapsed disease | Number of patients with PD1/PDL1 tumors |
|---|---|---|---|---|---|---|---|---|---|
| Gandhi et al. | 2018 | United States | NSCLC | 616 | Pembrolizumab | Placebo | 2:1 | Primary | 388 |
| Borghaei et al. | 2015 | USA | NSCLC | 792 | Nivolumab | Docetaxel | 1:1 | Relapsed | 246 |
| Zhou et al. | 2017 | China | NSCLC | 425 | Pembrolizumab | Docetaxel | 1:1 | Relapsed | 227 |
| Mok et al. | 2019 | USA | NSCLC | 1,274 | Pembrolizumab | Carboplatin & Paclitaxel OR Pemetrexed | 1:1 | Primary | 1,274 |
| Reck et al. | 2016 | China | NSCLC | 305 | Pembrolizumab | Carboplatin and Paclitaxel OR Gemcitabine and Cisplatin OR Gemcitabine & Carboplatin | 1:1 | Primary | 205 |
| Paz-Ares et al. | 2018 | Spain | NSCLC | 559 | Pembrolizumab | Placebo and Paclitaxel OR Nab-paclitaxel | 1:1 | Primary | 353 |
| Vokes et al. | 2018 | USA | NSCLC | 352 | Nivolumab | Docetaxel | 1:1 | Relapsed | 42 |
| Barlesi et al. | 2018 | Germany | NSCLC | 792 | Avelumab | Docetaxel | 1:1 | Primary | 529 |
| Rittmeyer et al. | 2017 | USA | NSCLC | 1,255 | Atezolizumab | Docetaxel | 1:1 | Primary | 463 |
| Carbone et al. | 2017 | USA | NSCLC | 1,325 | Nivolumab | Gemcitabine and Paclitaxel OR Pemetrexed | 1:1 | Relapsed | 423 |
| Wu et al. | 2019 | China | NSCLC | 639 | Nivolumab | Docetaxel | 2:1 | Relapsed | 252 |
| Pujade-Lauarine et al. | 2021 | USA | Ovarian | 556 | Avelumab OR Avelumab and Pegylated Liposomal Doxorubicin | Pegylated Liposomal Doxorubicin | 1:1 | Relapsed | 288 |
| Emens et al. | 2021 | USA | Breast | 902 | Atezolizumab and Nab-Paclitaxel | Nab-Paclitaxel and Placebo | 1:1 | Primary | 369 |
| Owonikoko et al. | 2021 | USA | SCLC | 555 | Nivolumab | Placebo | 1:1 | Primary | Unknown |
| Miles et al. | 2021 | USA | Breast | 651 | Atezolizumab and Paclitaxel | Paclitaxel and Placebo | 2:1 | Primary | 292 |
| Spigel et al. | 2021 | USA | SCLC | 803 | Nivolumab | Topotecan OR Amrubicin | 1:1 | Relapsed | Unknown |
| Shitara et al. | 2020 | USA | Gastric/GOJ | 763 | Pembrolizumab OR Pembrolizumab and Cisplatin OR 5-Fluorouracil OR Capecitabine | Placebo and Cisplatin OR 5-Fluorouracil OR Capecitabine | 1:1:1 | Primary | 763 |
| Shitara et al. | 2018 | USA | Gastric/GOJ | 570 | Pembrolizumab | Paclitaxel | 1:1 | Relapsed | 380 |
| Kojima et al. | 2020 | Japan | Oesophageal/GOJ | 628 | Pembrolizumab | Paclitaxel, Docetaxel, Irinotecan | 1:1 | Relapsed | 222 |
| Cohen et al. | 2019 | USA | HNSCC | 495 | Pembrolizumab | Methotrexate OR Docetaxel OR Cetuximab | 1:1 | Relapsed | 295 |
| Burtness et al. | 2019 | USA | HNSCC | 882 | Pembrolizumab OR Pembrolizumab and Cisplatin OR carboplatin and 5-Fluorouracil | EXTREME regimen | 1:1:1 | Primary | 754 |
| Ferris et al. | 2016 | USA | HNSCC | 502 | Nivolumab | Methotrexate OR docetaxel OR cetuximab | 2:1 | Relapsed | Unknown |
| Kang et al. | 2017 | Japan | Gastric/GOJ | 493 | Nivolumab | Placebo | 2:1 | Relapsed | Unknown |
| Bang et al. | 2018 | USA | GOJ | 371 | Avelumab and BSC | Irinotecan OR Paclitaxel & BSC | 1:1 | Relapsed | Unknown |
| Kim et al. | 2019 | China | Oesophageal/GOJ | 123 | Pembrolizumab | Paclitaxel OR Docetaxel OR Irinotecan | 1:1 | Relapsed | 54 |
| Fradet et al. | 2019 | Canada | Urothelial | 542 | Pembrolizumab | Paclitaxel OR Docetaxel OR Vinflunine | 1:1 | Relapsed | 230 |
| Winer et al. | 2021 | USA | Triple Negative Breast | 622 | Pembrolizumab | Capecitabine OR Eribulin, Gemcitabine OR Vinorelbine | 1:1 | Relapsed | 605 |
| Rudin et al. | 2020 | USA | SCLC | 453 | Pembrolizumab & Etoposide | Placebo & Etoposide | 1:1 | Primary | Unknown |
| Finn et al. | 2020 | USA | Hepatocellular | 413 | Pembrolizumab | Placebo and BSC | 2:1 | Relapsed | Unknown |
| Powles et al. | 2018 | United Kingdom | Urothelial Bladder | 931 | Atezolizumab | Paclitaxel OR Docetaxel OR Vinflunine | 1:1 | Relapsed | Unknown |
| Hamanishi et al. | 2021 | Japan | Ovarian | 316 | Nivolumab | Gemcitabine OR Pegylated Liposomal Doxorubicin | 1:1 | Relapsed | 123 |
| Jassem et al. | 2021 | USA | NSCLC | 572 | Atezolizumab | Cisplatin OR Carboplatin and Pemetrexed OR Gemcitabine | 1:1 | Primary | 554 |
| Motzer et al. | 2015 | USA | Renal Cell Carcinoma | 1,068 | Nivolumab | Everolimus | 1:1 | Relapsed | 181 |
| Horn et al. | 2018 | USA | SCLC | 403 | Atezolizumab & Carboplatin & Etoposide | Placebo and Carboplatin and Etoposide | 1:1 | Primary | Unknown |
| Antonia et al. | 2018 | USA | NSCLC | 713 | Durvulumab | Placebo | 2:1 | Relapsed | Unknown |
| Fennell et al. | 2021 | United Kingdom | Mesothelioma | 332 | Nivolumab | Placebo | 2:1 | Relapsed | 86 |
| Wu et al. | 2021 | China | NSCLC | 262 | Pembrolizumab | Carboplatin and Paclitaxel OR Pemetrexed | 1:1 | Primary | 262 |
GOJ, gastro-oesophageal junction adenocarcinoma; HNSCC, head and neck squamous cell carcinoma; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; EXTREME regimen, cetuximab, cisplatin and/or carboplatin, 5-fluorouracil; BSC, best supportive care.